bamobrien

Eric Ho

Eric Ho serves as Vice President, Medication Information for RxWiki Inc. an Austin-based digital media startup leveraging pharmacies and pharmacists as patient education experts digitally, on mobile, and in practice. He is responsible for development of RxWiki's content offerings including its pharmacist-written medication encyclopedia, medication and condition related multimedia, and clinically-oriented social and digital media content. As a practitioner, Eric has had experience in specialty sterile compounding, long term care pharmacy, and pharmacy leadership. He is currently a board member of the Texas Pharmacy Association (where he has been active legislatively and helped to develop the Texas Medicaid MTM pilot program), the Texas PharmPAC, and the University of Texas College of Pharmacy Alumni Association. In his spare time, Eric is a musical hobbyist and writes pharmacy and pharmaceutical commentary featured on the web and beyond.

bamobrien’s Activity

Tue Dec 31

NL

Article

bamobrien published an article 3:48 PM

Insurance Ups and Downs for Diabetes Drugs in 2014

Managed care titans CVS Caremark and Express Scripts are undertaking major changes to their preferred drug formularies that may significantly impact a number of well-known diabetes medications and manufacturers.

NL

Article

bamobrien published an article 2:15 PM

Zogenix, Zohydro ER Face Familiar Post-Approval Hurdles

In a familiar echo for pain medications in the past, state attorneys across the US have submitted new concerns over Zogenix and Zohydro ER that may seriously dampen its success or influence the FDA to recall Zohydro's approval entirely...

Mon Dec 30

NL

Article

bamobrien published an article 3:48 PM

Payor Trouble for Advair, GlaxoSmithKline Drugs in 2014

A number of well-known GlaxoSmithKline drugs, including one major blockbuster, will no longer be covered by the largest pharmacy benefit manager in the U.S. beginning Jan. 1.

Mon Dec 23

NL

Article

bamobrien published an article 6:30 PM

Rite Aid, Walgreen, and CVS: Can In-Store Care Push Pharmacy Stocks Forward?

The tide has turned dramatically for in-store care clinics at major pharmacy retailers over the last few years. While previously growth for these services had stalled due to lack of dialogue between providers, new waves of partnerships for CVS, [more]

Thu Dec 12

NL

Article

bamobrien published an article 2:08 PM

The Weight Loss Drug Company Investors Need to Watch Out For

Big names like GlaxoSmithKline, Arena, VIVUS, and Orexigen are probably well-known among obesity market watchers, but this less publicized company out of Massachusetts is poised to change the landscape in coming years.

Mon Dec 2

NL

Article

bamobrien published an article 4:52 PM

CVS Caremark's Big Thanksgiving Purchase: The Coram Buyout

The oft-overlooked home infusion and alternative site infusion market represents a huge opportunity for CVS Caremark with its recent acquisition of leading infusion provider Coram Specialty Infusion Services.

Tue Nov 26

NL

Article

bamobrien published an article 10:34 AM

The Good News, Bad News for Belviq: …Now the Good News

While Arena Pharmaceuticals' Belviq may need time to gain traction, it may have many of the right pieces in the right places to realize its long-term prospects

Fri Nov 15

NL

Article

bamobrien published an article 8:52 AM

Eteplirsen in Question: Hope for Sarepta

Recent decisions by the Food and Drug Administration poses new questions about Sarepta Therapeutics, eteplirsen, and the future of DMD treatment.

Wed Nov 6

NL

Article

bamobrien published an article 2:36 PM

Pain and Abuse: The Challenge in Bringing Zohydro to Market

Recent developments in controlled substance rules may help Zogenix's extended-release hydrocodone product to market when it will need all the help it can get.

Mon Nov 4

NL

Article

bamobrien published an article 11:34 AM

Walgreen and the Biggest Biotech Startup You've Never Heard Of

Walgreen's new partnership could change the way we think of pharmacies.

Mon Oct 21

NL

Article

bamobrien published an article 2:12 PM

The Clinical Lowdown: Keryx and Zerenex

A second opinion on the recent Keryx rush.

Mon Oct 14

NL

Article

bamobrien published an article 10:04 AM

MannKind Bulls Should Prepare for the Long Haul

Afrezza could be a blockbuster, but will physicians wait and see?

CAPS Stats & Trivia

CAPS Player Rating < 20
Player Rank 0 out of 75035
Score 0.00
Score Change Today 0
Accuracy 0.00%
Active Picks 0
Total Picks 0
Best Pick ( 0)
Worst Pick ( 0)
Average Score per Pick 0.00
Charms Earned 0
Highest Rated Favorite No Favorites Selected
Go to bamobrien’s CAPS page

Boards Stats & Trivia

Board Posts 0
Recs Received 0
People who have rec'd these posts 0
Recs to Posts Ratio (last 30 days) N/A
Threads Started 0
Threads Started Percentage 0.00 %
Most Frequent Board N/A
Very First Post N/A
Percentage of Posts Rec'd 100.00 %
Show bamobrien’s 10 Latest Posts